Skye Bioscience, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - SKYE

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Skye Bioscience, Inc. regarding a class action lawsuit due to allegations of misleading statements about the effectiveness of its lead product candidate, nimacimab, during the specified class period [1]. Group 1: Allegations and Class Period - The class period for the allegations is from November 4, 2024, to October 3, 2025 [1]. - The complaint claims that the defendants made materially false and misleading statements about nimacimab, asserting it was more effective than it actually was, which overstated its clinical, regulatory, and commercial prospects [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of SKYE during the class period are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the status of the case [2]. Group 3: Law Firm's Mission - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].